ABSTRACT
BACKGROUND:
All trans retinoic acid (ATRA) is used as standard of care in promyelocytic leukemia. Not much is known about the gene expression profile in ATRA-treated tongue cancer cells. We performed a genome-wide transcriptional profiling of ATRA-treated tongue cancer cells to understand the pathways that mediate ATRA action in tongue cancer.
METHODS:
We measured the effects of ATRA on the proliferation of SCC-9 human tongue carcinoma cells. The differential gene expression profile was measured by microarray analysis of untreated and ATRA-treated cells and expression of key genes was validated by real-time RT-PCR.
RESULTS:
ATRA treatment (24 and 48 hr) significantly inhibited SCC-9 cell proliferation in a dose-dependent manner. SCC-9 cells treated for 48 hr with ATRA showed upregulation of 276 genes, including ANGPTL4, GDF15, ICAM1 and TUSC4, and downregulation of 43 genes, including CXCL10. Validation by real-time PCR showed a significant upregulation of intracellular adhesion molecule 1 (ICAM1) and downregulation of CXCL10 and IL32.
CONCLUSIONS:
ATRA had an anti-tumor effect in tongue cancer cells. This effect is likely mediated via upregulation of ICAM1 and downregulation of CXCL10 and IL32.
Genome-wide transcriptional profiling analysis of all trans retinoic acid-treated tongue carcinoma SCC-9 cells
Riferimento:
J Surg Oncol. 2011 Dec;104(7):830-5.
Autori:
Dai Y, Wang J, Xia J, Hong Y, Chen N, Cheng B.
Fonte:
J Surg Oncol. 2011 Dec;104(7):830-5.
Anno:
2011
Azione:
L'acido all-trans retinoico (ATRA) ha un effetto anti-tumorale, dose dipendente, sulla linea cellulare del tumore alla lingua.
Target:
ATRA/tumore lingua.
Sostanze:
